Bristol Myers BMY depends on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee ...

In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Currently, Alphamab trades at a price-to-earnings (P/E) ratio of 44 times, even higher than the 30 times for Henlius Biotech ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

ET Net News Agency, 17 June 2025] SINO BIOPHARM (01177) fell 2.8% to HK$5.13. It hits an intra-day low of HK$5.12, and an intra-day high of HK$5.36. The total shares traded was 49.62 million, with a ...

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into ...

China's biotechnology stocks have experienced a significant rally, outperforming AI, with a 60% surge since January due to billion-dollar foreign licensing deals.

The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation ...